Citigroup Inc Ventyx Biosciences, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 45,948 shares of VTYX stock, worth $104,301. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,948

Previous 17,855 157.34%

Holding current value

$104,301

Previous $41,000 143.9%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.85 - $3.2 $51,972 - $89,897	28,093 Added 157.34%	45,948 $100,000
Q2 2024 Aug 12, 2024	BUY	$2.31 - $5.59 $13,841 - $33,495	5,992 Added 50.51%	17,855 $41,000
Q1 2024 May 10, 2024	BUY	$1.9 - $10.13 $3,893 - $20,756	2,049 Added 20.88%	11,863 $65,000
Q4 2023 Feb 09, 2024	SELL	$2.08 - $31.18 $684 - $10,258	-329 Reduced 3.24%	9,814 $24,000
Q3 2023 Nov 09, 2023	SELL	$29.8 - $40.3 $1.06 Million - $1.43 Million	-35,507 Reduced 77.78%	10,143 $352,000
Q2 2023 Aug 10, 2023	BUY	$28.53 - $39.55 $1.04 Million - $1.44 Million	36,388 Added 392.87%	45,650 $1.5 Million
Q1 2023 May 11, 2023	BUY	$29.51 - $46.65 $128,220 - $202,694	4,345 Added 88.37%	9,262 $310,000
Q4 2022 Feb 09, 2023	BUY	$24.16 - $36.38 $60,617 - $91,277	2,509 Added 104.19%	4,917 $161,000
Q3 2022 Nov 10, 2022	SELL	$12.64 - $38.7 $1.54 Million - $4.73 Million	-122,104 Reduced 98.07%	2,408 $84,000
Q2 2022 Aug 10, 2022	BUY	$11.95 - $18.75 $1.48 Million - $2.33 Million	124,105 Added 30492.63%	124,512 $1.52 Million
Q1 2022 May 12, 2022	SELL	$10.0 - $19.98 $24,190 - $48,331	-2,419 Reduced 85.6%	407 $6,000
Q4 2021 Feb 10, 2022	BUY	$14.2 - $23.07 $40,129 - $65,195	2,826 New	2,826 $56,000

Others Institutions Holding VTYX

# of Institutions

125

Shares Held

52.9M

Call Options Held

35.3K

Put Options Held

83K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account